ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AUPH Aurinia Pharmaceuticals Inc

5.09
0.08 (1.60%)
After Hours
Last Updated: 21:55:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aurinia Pharmaceuticals Inc NASDAQ:AUPH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.08 1.60% 5.09 5.09 5.22 5.18 4.98 5.10 1,581,051 21:55:00

Report of Foreign Issuer (6-k)

24/05/2017 11:06am

Edgar (US Regulatory)



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 6-K


  REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

Dated May 17, 2017

Commission File Number 001-36421


AURINIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)


N/A
(Translation of Registrant’s Name)

#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250) 708-4272
(Address and telephone number of registrant’s principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F       Form 40-F 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes        No  

This Form 6-K is hereby filed and incorporated by reference into the Registrant’s Registration Statement on Form F-10 (File No. 333-206994).



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated:

May 17, 2017

 

Aurinia Pharmaceuticals Inc.

 

 

 

By:

/s/ Celia Economides

 

Name:

Celia Economides

 

 

Title:

Head of IR & Communications

2

EXHIBIT INDEX

Exhibit

 

Description of Exhibit

 
99.1

News Release – AURINIA DOSES FIRST PATIENT IN AURORA PHASE 3 CLINCAL TRIAL OF VOCLOSPORIN IN LUPUS NEPHRITIS




Exhibit 99.1 included with this report on Form 6-K is hereby incorporated by reference as an exhibit to the Registrant’s Registration Statement on Form F-10 (File No. 333-206994), as amended or supplemented.

3

1 Year Aurinia Pharmaceuticals Chart

1 Year Aurinia Pharmaceuticals Chart

1 Month Aurinia Pharmaceuticals Chart

1 Month Aurinia Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock